GH Research PLC (NASDAQ:GHRS) Given Average Rating of “Moderate Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $40.3750.

A number of brokerages have recently commented on GHRS. HC Wainwright dropped their price target on GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Needham & Company LLC increased their target price on GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Cantor Fitzgerald increased their target price on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Finally, Guggenheim set a $34.00 price target on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th.

GH Research Stock Up 4.2%

Shares of NASDAQ GHRS opened at $24.60 on Thursday. GH Research has a twelve month low of $11.32 and a twelve month high of $25.94. The stock’s 50 day moving average price is $21.32 and its 200-day moving average price is $17.14. The company has a market capitalization of $1.69 billion, a PE ratio of -26.74 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). As a group, research analysts expect that GH Research will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Lynx1 Capital Management LP increased its holdings in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after purchasing an additional 1,854,238 shares during the period. RTW Investments LP increased its stake in GH Research by 6.5% in the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock valued at $75,359,000 after acquiring an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in GH Research in the fourth quarter valued at $22,860,000. Troluce Capital Advisors LLC increased its stake in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Finally, Millennium Management LLC increased its stake in GH Research by 324.1% in the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after acquiring an additional 659,957 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.